BIA response to MHRA consultation on clinical trials legislative proposals

This consolidated BIA response was developed with input from our Regulatory Affairs Advisory Committee and submitted using the online survey providing our comments in response to questions raised in the MHRA consultation document on proposals to update the current UK clinical trials legislation, the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended. This will provide the opportunity to design a world-class regulatory environment for clinical trials to support the development of new innovative medicines and ensure that the UK retains and grows its reputation as world leading base for life sciences, in line with the ambitions of the Life Sciences Vision.